<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REZIRA- hydrocodone bitartrate and pseudoephedrine hydrochloride solution </strong><br>Hawthorn Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use REZIRA Oral Solution safely and effectively. See full prescribing information for REZIRA Oral Solution. CII <br>REZIRA (hydrocodone bitartrate and pseudoephedrine hydrochloride) Oral Solution <br>Initial U.S. Approval: 2011</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">REZIRA Oral Solution is a combination product containing an antitussive and nasal decongestant indicated for: </p>
<ul><li>Relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> associated with <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>. (<a href="#i4i_section_id_cb7a1dd9-fd87-4c46-a835-a36597e7293c">1.1</a>)</li></ul>
<p class="Highlighta"><span class="Underline">Important Limitations of Use:</span><br>Not indicated for pediatric patients under 18 years of age </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For oral use only. </p>
<ul><li>Adults 18 years of age and older: 5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours. (<a href="#i4i_section_id_f5c936a1-71e5-428c-830f-1fabcea8a88a">2.1</a>)</li></ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each 5 mL of REZIRA Oral Solution contains: hydrocodone bitartrate, USP, 5 mg; and pseudoephedrine hydrochloride, USP, 60 mg. (<a href="#i4i_dosage_form_strength_id_12d2e822-a463-4cd3-916d-bf57297d38bd">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, pseudoephedrine hydrochloride, or any of the inactive ingredients of REZIRA. (<a href="#i4i_contraindications_id_31b52089-d509-4925-869d-22f80ea8b1c4">4</a>)</li>
<li>Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy. (<a href="#i4i_contraindications_id_31b52089-d509-4925-869d-22f80ea8b1c4">4</a>)</li>
<li>Patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<a href="#i4i_contraindications_id_31b52089-d509-4925-869d-22f80ea8b1c4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>: Use with caution. (<a href="#i4i_precautions_general_id_b7f24786-2a50-4f5e-9824-401412a48640">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>: Prescribe with caution that is appropriate to the use of other opioids. (<a href="#i4i_section_id_5dee308d-12c4-492c-a447-cdaa3e8a7d14">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>: Avoid in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. (<a href="#i4i_section_id_0afacbfe-bf27-4a8a-828e-b8d1977dda06">5.3</a>)</li>
<li>Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. (<a href="#i4i_section_id_5a8cad4f-dc44-40f6-a5bd-5e940e21e200">5.4</a>)</li>
<li>Acute abdominal conditions: Use with caution in patients with acute abdominal conditions. (<a href="#i4i_section_id_4ea67fba-5567-4c5d-8b7a-5e24312bb7f3">5.5</a>)</li>
<li>Coexisting conditions: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#i4i_section_id_9ba411ee-3e15-4541-ac53-aefd5e26739d">5.10</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions of REZIRA Oral Solution include: </p>
<p class="Highlighta">Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. (<a href="#i4i_adverse_effects_id_20f97649-5319-4a26-abd3-ba54f89abde5">6</a>) </p>
<p class="Highlighta"><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hawthorn Pharmaceuticals, Inc. at tel:1-800-793-2145 and www.hawthornrx.com or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants may exhibit additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. Avoid using with REZIRA Oral Solution. (<a href="#i4i_section_id_775f17d7-cf79-42d9-91bf-159343ccaef7">7.1</a>)</li>
<li>MAOIs or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or hydrocodone, may cause increase in blood pressure or <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> may occur. (<a href="#i4i_section_id_6b302ac4-41b0-4284-bef9-3d6c706c7200">7.2</a>)</li>
<li>Anticholinergic drugs: Use with caution in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects. (<a href="#i4i_section_id_4a3706ab-1b94-45e0-8e92-01dec552fcf9">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_id_c9cbeb6f-6b82-48c6-b9ff-9920121d4eb6">8.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_0fda0bcb-2ebc-49d3-ae51-aaf9c9ad4f85">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Common Cold</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults 18 Years of Age and Older</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Acute Abdominal Conditions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Co-administration with Anticholinergics</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Co-administration with MAOIs or Tricyclic Antidepressants</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Cardiovascular and Central Nervous System Effects</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Dosing</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Coexisting Conditions</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticholinergic Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Overdosage</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Dosing</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Concomitant Use of Alcohol and Other Central Nervous System Depressants</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 Activities Requiring Mental Alertness</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></a></h2>
<h2><a href="#section-16.6" class="toc">17.6 MAOIs</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4cfa2406-7e81-4508-b874-1ec70e848619"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb7a1dd9-fd87-4c46-a835-a36597e7293c"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Common Cold</span></h2>
<p class="First">REZIRA<span class="Sup">®</span> Oral Solution (hydrocodone bitartrate and pseudoephedrine hydrochloride) is indicated for:</p>
<p>Relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> associated with <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</p>
<p><span class="Underline">Important Limitations of Use:</span></p>
<p>Not indicated for pediatric patients under 18 years of age <span class="Italics">[see Pediatric Use (<a href="#i4i_pediatric_use_id_44d0cf62-1d5e-4222-8c9b-1a6623247fe8">8.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_27d3d850-4674-4775-8aab-df6fe1397a41"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Administer REZIRA Oral Solution by the oral route only.  Measure REZIRA Oral Solution with an accurate milliliter measuring device.  Do not use a household teaspoon to measure the dose <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_54922124-459b-4852-b2a0-37b3ffdf2166">5.9</a>)]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5c936a1-71e5-428c-830f-1fabcea8a88a"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults 18 Years of Age and Older</h2>
<p class="First">5 mL every 4 to 6 hours as needed, not to exceed 4 doses (20 mL) in 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_12d2e822-a463-4cd3-916d-bf57297d38bd"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">REZIRA is a clear, colorless to light yellow, grape-flavored liquid.</p>
<p>Each 5 mL of REZIRA Oral Solution contains: hydrocodone bitartrate, USP, 5 mg; and pseudoephedrine hydrochloride, USP, 60 mg <span class="Italics">[see Description (<a href="#i4i_description_id_8959e840-6f52-4082-b71c-1718e599701f">11</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_31b52089-d509-4925-869d-22f80ea8b1c4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">REZIRA Oral Solution is contraindicated in:</p>
<ul>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, pseudoephedrine hydrochloride, or any of the inactive ingredients of REZIRA Oral Solution.</li>
<li>Patients receiving MAOI therapy or within 14 days of stopping such therapy <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_6b302ac4-41b0-4284-bef9-3d6c706c7200">7.2</a>)]</span>.</li>
<li>Patients with narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_bc584002-bed5-42e2-9be7-518712a13b94"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b7f24786-2a50-4f5e-9824-401412a48640"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in REZIRA Oral Solution, produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of hydrocodone bitartrate in adults has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Exercise caution when administering REZIRA Oral Solution because of the potential for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated <span class="Italics">[see Overdosage (<a href="#i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762">10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5dee308d-12c4-492c-a447-cdaa3e8a7d14"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of REZIRA Oral Solution.  Prescribe and administer REZIRA with the same degree of caution appropriate to the use of other opioid drugs <span class="Italics">[see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#i4i_abuse_id_a568f82b-8569-4ecc-b9ad-e874e5d3fa28">9.2</a>, <a href="#i4i_dependence_id_616aa92b-7307-4c6e-8c61-f74062022650">9.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0afacbfe-bf27-4a8a-828e-b8d1977dda06"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of REZIRA Oral Solution should be avoided in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a8cad4f-dc44-40f6-a5bd-5e940e21e200"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Activities Requiring Mental Alertness</h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in REZIRA Oral Solution, may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of REZIRA Oral Solution. Concurrent use of REZIRA Oral Solution with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ea67fba-5567-4c5d-8b7a-5e24312bb7f3"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Acute Abdominal Conditions</h2>
<p class="First">REZIRA Oral Solution should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_4a3706ab-1b94-45e0-8e92-01dec552fcf9">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_512e81bb-a0aa-4489-8edc-18eca4bf1162"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Co-administration with Anticholinergics</h2>
<p class="First">The concurrent use of anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.  Exercise caution when using REZIRA Oral Solution in patients taking anticholinergic medications <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_4a3706ab-1b94-45e0-8e92-01dec552fcf9">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2f51d6a5-be9a-4dff-9413-fbdfab3e784d"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Co-administration with MAOIs or Tricyclic Antidepressants</h2>
<p class="First">REZIRA Oral Solution should not be used in patients receiving MAOI therapy or within 14 days of stopping such therapy as an increase in blood pressure or <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, may occur. In addition, the use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate, one of the active ingredients in REZIRA Oral Solution, may increase the effect of either the antidepressant or hydrocodone <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_31b52089-d509-4925-869d-22f80ea8b1c4">4</a>) and Drug Interactions (<a href="#i4i_section_id_6b302ac4-41b0-4284-bef9-3d6c706c7200">7.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c75cbf0-75aa-48ea-92bf-3f1106926d9e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Cardiovascular and Central Nervous System Effects</h2>
<p class="First">The pseudoephedrine hydrochloride contained in REZIRA Oral Solution can produce cardiovascular and central nervous system effects in some patients such as <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.  In addition, central nervous system stimulation with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> with accompanying <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been reported. Therefore, REZIRA Oral Solution should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, and should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54922124-459b-4852-b2a0-37b3ffdf2166"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Dosing</h2>
<p class="First">Patients should be advised to measure REZIRA Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions <span class="Italics">[see Overdosage (<a href="#i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762">10</a>)]</span>. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ba411ee-3e15-4541-ac53-aefd5e26739d"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Coexisting Conditions</h2>
<p class="First">REZIRA Oral Solution should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fbae602-f7d2-428b-867b-f1b3871db595"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">REZIRA Oral Solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Use in Specific Populations (<a href="#i4i_section_id_c9cbeb6f-6b82-48c6-b9ff-9920121d4eb6">8.6</a>); Pharmacokinetics (<a href="#i4i_pharmacokinetics_id_e34a02ea-2290-4149-816e-20da81f69fe3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd41141f-a17f-4dfe-875d-f555bbe72325"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">REZIRA Oral Solution should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Use in Specific Populations (<a href="#i4i_section_id_0fda0bcb-2ebc-49d3-ae51-aaf9c9ad4f85">8.7</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_20f97649-5319-4a26-abd3-ba54f89abde5"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Use of hydrocodone bitartrate, a semisynthetic opioid, may result in the following:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_precautions_general_id_b7f24786-2a50-4f5e-9824-401412a48640">5.1</a>) and Overdosage (<a href="#i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762">10</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_5dee308d-12c4-492c-a447-cdaa3e8a7d14">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_0afacbfe-bf27-4a8a-828e-b8d1977dda06">5.3</a>) and Overdosage (<a href="#i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762">10</a>)]</span>
</li>
<li>Decreased mental alertness with impaired mental and/or physical abilities <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_5a8cad4f-dc44-40f6-a5bd-5e940e21e200">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_4ea67fba-5567-4c5d-8b7a-5e24312bb7f3">5.5</a>)]</span>
</li>
</ul>
<p>Use of pseudoephedrine, a sympathomimetic amine, may result in the following:</p>
<ul>
<li>Central nervous system effects such as <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_2c75cbf0-75aa-48ea-92bf-3f1106926d9e">5.8</a>)]</span>
</li>
<li>Cardiovascular system effects such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> with accompanying <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_2c75cbf0-75aa-48ea-92bf-3f1106926d9e">5.8</a>)]</span>
</li>
</ul>
<p>The most common adverse reactions are central nervous system and cardiovascular reactions and include the following: Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.</p>
<p>Other adverse reactions include:</p>
<p>Gastrointestinal System: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (more frequent in ambulatory than in recumbent patients), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p>Genitourinary System: Ureteral spasm, spasm of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> sphincters, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p>Cardiovascular System: Fast, slow heartbeat, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like state, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p>Dermatological System: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a0b18c59-62c2-42ba-94dd-4262cc3a4234"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No specific interaction studies have been conducted with REZIRA Oral Solution.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_775f17d7-cf79-42d9-91bf-159343ccaef7"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</h2>
<p class="First">The use of opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants concomitantly with REZIRA Oral Solution may cause an additive CNS depressant effect and should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b302ac4-41b0-4284-bef9-3d6c706c7200"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants</h2>
<p class="First">Do not prescribe REZIRA Oral Solution if the patient is taking a prescription MAOI (i.e., certain drugs used for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone. An increase in blood pressure or <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> may also occur when pseudoephedrine containing preparations are used with MAOIs <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_2f51d6a5-be9a-4dff-9413-fbdfab3e784d">5.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a3706ab-1b94-45e0-8e92-01dec552fcf9"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticholinergic Drugs</h2>
<p class="First">Hydrocodone should be administered cautiously to persons receiving anticholinergic drugs in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_512e81bb-a0aa-4489-8edc-18eca4bf1162">5.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_6545b43a-845f-48df-857c-b30e94830109"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b0143057-3993-4f54-a6e2-2bc211e89881"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Teratogenic Effects:</span> Pregnancy Category C </p>
<p>There are no adequate and well controlled studies of REZIRA Oral Solution in pregnant women. Reproductive toxicity studies have not been conducted with REZIRA Oral Solution; however, studies are available with an individual active ingredient or related active ingredient. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats.  Because animal reproduction studies are not always predictive of human response, REZIRA Oral Solution should be used during pregnancy only if the benefit justifies the potential risk to the fetus. </p>
<p><span class="Underline">Hydrocodone:</span></p>
<p>Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 35 times the maximum recommended human daily dose (MRHDD) (on a mg/m<span class="Sup">2</span> basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 50 times the MRHDD of hydrocodone (on a mg/m<span class="Sup">2</span> basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity.  In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 25 and 120 times, respectively, the MRHDD of hydrocodone (on a mg/m<span class="Sup">2</span> basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.</p>
<p><span class="Italics">Nonteratogenic Effects:</span> Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_a99cf6b9-bd2e-409e-8d95-700d9ff4ba0a"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">As with all opioids, administration of REZIRA Oral Solution to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ca831024-b253-468a-be1b-d6c2783a869c"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when REZIRA is administered to nursing mothers. Hydrocodone and pseudoephedrine are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from REZIRA Oral Solution, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_44d0cf62-1d5e-4222-8c9b-1a6623247fe8"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of REZIRA Oral Solution in pediatric patients under 18 years of age have not been established. The use of hydrocodone in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_precautions_general_id_b7f24786-2a50-4f5e-9824-401412a48640">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_66bf8173-b3e2-4478-897a-a8e45f90e2fb"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies have not been conducted with REZIRA Oral Solution. Other reported clinical experience with the individual active ingredients of REZIRA Oral Solution has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The pseudoephedrine contained in REZIRA Oral Solution is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c9cbeb6f-6b82-48c6-b9ff-9920121d4eb6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">REZIRA Oral Solution should be given with caution in patients with severe impairment of renal function. Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver. Therefore, pseudoephedrine may accumulate in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fda0bcb-2ebc-49d3-ae51-aaf9c9ad4f85"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">REZIRA Oral Solution should be given with caution in patients with severe impairment of hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_e093036e-01bb-4927-b913-0025d0e1dc5a"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="i4i_controlled_substance_id_26f96350-2ebe-4115-911b-89478e639ac9"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">REZIRA Oral Solution is a Schedule II controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_a568f82b-8569-4ecc-b9ad-e874e5d3fa28"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of REZIRA Oral Solution, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="i4i_dependence_id_616aa92b-7307-4c6e-8c61-f74062022650"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of opioids; therefore, REZIRA Oral Solution should be prescribed and administered with caution. </p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of opioid therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No human overdosage data are available for REZIRA Oral Solution.</p>
<p><span class="Underline">Hydrocodone</span>:</p>
<p>Overdosage with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
<p><span class="Underline">Pseudoephedrine</span>:</p>
<p>Overdosage with sympathomimetics, such as pseudoephedrine, may give rise to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">giddiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">precordial pain</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">difficulty in micturition</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> and <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tenseness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.  Many patients can present a toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> with <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span> and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>.  Some may develop <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>.</p>
<p>Treatment of overdosage consists of discontinuation of REZIRA Oral Solution together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8959e840-6f52-4082-b71c-1718e599701f"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">REZIRA Oral Solution contains hydrocodone bitartrate (a semisynthetic centrally-acting opioid antitussive) and pseudoephedrine hydrochloride (a sympathomimetic amine).</p>
<p>Each 5 mL dose of REZIRA Oral Solution contains: hydrocodone bitartrate, USP, 5 mg; and pseudoephedrine hydrochloride, USP, 60 mg.</p>
<p>REZIRA Oral Solution also contains: citric acid anhydrous, glycerin, grape flavor, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate, sodium saccharin, and sucrose.</p>
<p>Hydrocodone bitartrate is morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5α)-, [<span class="Italics">R</span>-(<span class="Italics">R</span>*,<span class="Italics">R</span>*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5); also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); a fine white crystal or crystalline powder, which is derived from the opium alkaloid, thebaine; and may be represented by the following structural formula:</p>
<div class="Figure">
<img alt="Hydrocodone Bitartrate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b873615-d90e-41a1-acc6-60f0526eeead&amp;name=rezira-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Pseudoephedrine hydrochloride is benzenemethanol, α-[1-(methylamino)ethyl]-, [<span class="Italics">S</span>-(<span class="Italics">R</span>*,<span class="Italics">R</span>*)] hydrochloride and has the following chemical structure:</p>
<div class="Figure">
<img alt="Chemical Structure for Pseudoephedrine Hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b873615-d90e-41a1-acc6-60f0526eeead&amp;name=rezira-02.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_2e01f966-aa66-47fb-adaa-869de8f34491"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_abf02355-8ed7-4c3f-90ee-3f36de207ce5"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, and physical and physiological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Pseudoephedrine hydrochloride is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine hydrochloride is recognized as an effective agent for the relief of <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> due to the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_e34a02ea-2290-4149-816e-20da81f69fe3"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate and pseudoephedrine hydrochloride after single-dose administration of 5 mg hydrocodone and 60 mg pseudoephedrine are equivalent to respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL) and 5 mL pseudoephedrine hydrochloride (60 mg/5 mL).</p>
<p>Hydrocodone had a mean (SD) peak plasma concentration of 10.6 (2.63) ng/mL at 1.4 (0.55) hours.  The mean plasma half-life of hydrocodone is approximately 4.9 hours.  Pseudoephedrine had a mean (SD) peak plasma concentration of 212 (46.2) ng/mL at 1.8 (0.56) hours.  The mean plasma half-life of pseudoephedrine is approximately 5.6 hours.  </p>
<p><span class="Bold"><span class="Italics">Specific Populations</span></span></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>Pseudoephedrine is primarily excreted unchanged in the urine as unchanged drug with the remainder apparently being metabolized in the liver.  Therefore, pseudoephedrine may accumulate in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_f0a930cc-44e4-4c90-8d09-4ed43b05bf57"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8d1a51e0-7f57-4be2-a5b8-295c22dfa33e"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with REZIRA Oral Solution; however, published information is available for the individual active ingredients or related active ingredients.</p>
<p><span class="Underline">Hydrocodone:</span></p>
<p>Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 30 and 80 times, respectively, the MRHDD of hydrocodone on a mg/m<span class="Sup">2</span> basis).</p>
<p><span class="Underline">Pseudoephedrine:</span></p>
<p>Two-year feeding studies in rats and mice demonstrated no evidence of carcinogenic potential with ephedrine sulfate, a structurally related drug with pharmacological properties similar to pseudoephedrine, at dietary doses up to 10 and 27 mg/kg, respectively (approximately 0.3 and 0.5 times, respectively, the MRHDD of pseudoephedrine hydrochloride on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_2d889527-671e-400c-b981-3b8ab2b2b346"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Efficacy studies were not conducted with REZIRA Oral Solution.  Efficacy of REZIRA Oral Solution is based on demonstration of bioequivalence to the individual reference products <span class="Italics">[see Pharmacokinetics (<a href="#i4i_pharmacokinetics_id_e34a02ea-2290-4149-816e-20da81f69fe3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ee77ff94-8df0-416f-8cc4-088fc771e5ea"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">REZIRA Oral Solution is supplied as a clear, colorless to light yellow, grape-flavored solution containing 5 mg hydrocodone bitartrate and 60 mg pseudoephedrine hydrochloride in each 5 mL. It is available in:</p>
<p>White HDPE bottles of one pint (480 mL): NDC 63717-875-16</p>
<p>Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_80f75575-d915-407a-b3fd-4f5eadb26aa8"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See FDA-Approved Patient Labeling]</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_977e1f84-570d-4b6e-9222-482f8c0272d7"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Overdosage</h2>
<p class="First">Patients should be advised not to increase the dose or dosing frequency of REZIRA Oral Solution because serious adverse events such as <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur with overdosage <span class="Italics">[see Warnings and Precautions (<a href="#i4i_precautions_general_id_b7f24786-2a50-4f5e-9824-401412a48640">5.1</a>); Overdosage (<a href="#i4i_overdosage_id_9440f5d8-f5df-4e03-a46a-635d9ab95762">10</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2910cad-9e6d-4c54-ab7c-b048fe665ba6"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Dosing</h2>
<p class="First">Patients should be advised to measure REZIRA Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured.  Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose <span class="Italics">[see Dosing and Administration (<a href="#i4i_dosage_admin_id_27d3d850-4674-4775-8aab-df6fe1397a41">2</a>) Warnings and Precautions (<a href="#i4i_section_id_54922124-459b-4852-b2a0-37b3ffdf2166">5.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4cc45a3e-55e5-410e-bc38-6f9a8503877c"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Concomitant Use of Alcohol and Other Central Nervous System Depressants</h2>
<p class="First">Patients should be advised to avoid the use of alcohol and other central nervous system depressants while taking REZIRA Oral Solution because additional reduction in mental alertness may occur <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_5a8cad4f-dc44-40f6-a5bd-5e940e21e200">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b302ecd-4b1e-4fa6-92cf-8492951efe48"></a><a name="section-16.4"></a><p></p>
<h2>17.4 Activities Requiring Mental Alertness</h2>
<p class="First">Patients should be advised to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as REZIRA Oral Solution may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_5a8cad4f-dc44-40f6-a5bd-5e940e21e200">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6836f634-bbd5-4041-856c-1ab79ff7f995"></a><a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></h2>
<p class="First">Patients should be cautioned that REZIRA Oral Solution contains hydrocodone bitartrate and can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_5dee308d-12c4-492c-a447-cdaa3e8a7d14">5.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a539138f-ea50-44f1-874d-cbf9d03e05de"></a><a name="section-16.6"></a><p></p>
<h2>17.6 MAOIs</h2>
<p class="First">Patients should be informed that due to its pseudoephedrine component, they should not use REZIRA Oral Solution with a MAOI or within 14 days of stopping the use of an MAOI <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_2f51d6a5-be9a-4dff-9413-fbdfab3e784d">5.7</a>)]</span>.</p>
<p>Manufactured for: Hawthorn Pharmaceuticals, Inc., Morristown, NJ  07960</p>
<p>REZIRA Oral Solution is a Registered Trademark of Hawthorn Pharmaceuticals, Inc.</p>
<p>Copyright © Hawthorn Pharmaceuticals, Inc.</p>
<p>HI246 </p>
<p>Rev 09/2014 </p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_69386944-846c-4c33-8bf3-90c8000e512b"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel - 480 mL Bottle Label</h1>
<p class="First">NDC 63717-875-16</p>
<p><span class="Bold">REZIRA<span class="Sup">®</span> CII</span><br>(Hydrocodone Bitartrate and<br>Pseudoephedrine HCl) Oral Solution</p>
<p>5 mg/60 mg per 5 mL</p>
<p><span class="Bold">Contains:</span><br>Hydrocodone <br>Bitartrate 5 mg/5 mL<br><span class="Bold">WARNING: May be habit forming.</span><br>Pseudoephedrine <br>Hydrochloride 60 mg/5 mL 						</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">HAWTHORN</span><br>PHARMACEUTICALS, INC.</p>
<p><span class="Bold">16 fl oz (480 mL)</span></p>
<div class="Figure"><img alt="Principal Display Panel - 480 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b873615-d90e-41a1-acc6-60f0526eeead&amp;name=rezira-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d615c40a-b5b5-4c65-a0e2-b4ef6d9b068f"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel - 5 mL Bottle Label</h1>
<p class="First">NDC 63717-875-99</p>
<p><span class="Bold">REZIRA<span class="Sup">®</span> CII</span><br>(Hydrocodone Bitartrate and<br>Pseudoephedrine HCl) Oral Solution</p>
<p>5 mg/60 mg per 5 mL</p>
<p><span class="Bold">Contains:</span><br>Hydrocodone Bitartrate 5 mg/5 mL<br><span class="Bold">WARNING: May be habit forming.</span><br>Pseudoephedrine Hydrochloride 60 mg/5 mL 						</p>
<p><span class="Bold">Rx Only<br>5 mL</span></p>
<p><span class="Bold">PROFESSIONAL SAMPLE - NOT FOR RESALE</span></p>
<div class="Figure"><img alt="Principal Display Panel - 5 mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7b873615-d90e-41a1-acc6-60f0526eeead&amp;name=rezira-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REZIRA 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate, pseudoephedrine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63717-875</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PSEUDOEPHEDRINE HYDROCHLORIDE</strong> (PSEUDOEPHEDRINE) </td>
<td class="formItem">PSEUDOEPHEDRINE HYDROCHLORIDE</td>
<td class="formItem">60 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GRAPE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (colorless to light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">GRAPE</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63717-875-16</td>
<td class="formItem">480 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63717-875-99</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022442</td>
<td class="formItem">06/08/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hawthorn Pharmaceuticals, Inc.
							(118049704)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0bbc5329-a003-4cce-acfb-22dcd3a851d6</div>
<div>Set id: 7b873615-d90e-41a1-acc6-60f0526eeead</div>
<div>Version: 4</div>
<div>Effective Time: 20140929</div>
</div>
</div> <div class="DistributorName">Hawthorn Pharmaceuticals, Inc.</div></p>
</body></html>
